Who to call at AEON Biopharma, Inc., and when
Fundz watches for the moments AEON Biopharma, Inc. starts buying, and tells you who to reach.
- An alert the day AEON Biopharma, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at AEON Biopharma, Inc., from your own LinkedIn network
AEON Biopharma, Inc.
The company shared information publicly (Regulation FD). An 8-K is the notice a US public company must file within four business days of a major event.
AI Executive Summary
AI-powered analysis of 8-K filing content
AEON Biopharma received official FDA meeting minutes from a Type 2b biosimilar development meeting for ABP-450, marking a critical regulatory milestone that will inform the company's continued development strategy for this drug candidate.
Key Takeaways
AEON Biopharma received official minutes from an FDA Type 2b meeting regarding ABP-450 biosimilar development
This represents a significant regulatory milestone in the development pathway for the company's biosimilar product portfolio
2 more takeaways
Related Filings (4)
4 more filings from AEON Biopharma, Inc. in the last 90 days
Filing Overview
What This Means
AEON Biopharma, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.